Is CBZ a Buy or a Sell? The Bull and Bear Case (2026)
Last updated July 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for CBIZ (CBZ) rests on Marcum integration and scale synergies: The 2024 Marcum acquisition roughly doubled CBIZ's size and created the largest middle-market accounting and advisory platform in the US. The bear case rests on cBIZ carries acquisition-related debt from the Marcum deal, so higher-for-longer interest rates and slower deleveraging are a risk to earnings. Analysts covering it publish targets from $42.00 to $46.00 against a $54.54 price, so even the professionals disagree by 9% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
CBIZ, Inc. is a national professional-services firm that provides accounting and tax, financial advisory and consulting, employee benefits consulting, property and casualty insurance brokerage, and technology and managed IT services, primarily to middle-market businesses. It reports through three segments: Financial Services (the largest, covering accounting, tax, and advisory), Benefits and Insurance Services, and National Practices. Much of its revenue is recurring and fee-based, tied to compliance calendars, benefits renewals, and long-standing client relationships rather than a single product cycle. Its November 2024 acquisition of Marcum LLP, valued at roughly $2.3 billion, was the largest deal in its history and roughly doubled the company's scale, pushing combined annualized revenue toward $2.8 billion and making CBIZ the largest advisor of its kind in the US. The investment picture centers on integration and margin execution. Full-year 2025 revenue rose about 52% on the Marcum deal, and adjusted earnings grew sharply, but 2026 organic growth is guided to a more modest 2% to 5% as the one-time acquisition boost laps. Management has framed 2026 around finishing the Marcum integration, applying technology and AI to service delivery, and returning cash through buybacks. Underlying operating margins have softened as integration, technology, and facility costs work through the model, and reported quarterly profit has at times been flattered by acquisition-related accounting gains, so investors tend to focus on adjusted EBITDA and free cash flow to judge the true run-rate.
The bull case: what would have to be true for $46.00
The most optimistic published target on CBZ is $46.00, -15.7% from the $54.54 price as of July 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Marcum integration and scale synergies
The 2024 Marcum acquisition roughly doubled CBIZ's size and created the largest middle-market accounting and advisory platform in the US. Management has said integration is largely complete with synergies tracking ahead of plan, which supports adjusted EBITDA of roughly $465 million to $475 million guided for 2026. Realizing cost savings and cross-selling across the enlarged client base is the central lever on profitability.
2. Recurring, fee-based revenue base
A large share of CBIZ revenue comes from recurring accounting, tax, benefits, and insurance work tied to regulatory and renewal calendars rather than discretionary spending. This gives the top line more stability than project-driven consultancies. The business does carry seasonality, with the first half weighted toward tax-season activity.
3. Technology, AI, and margin discipline
Management has positioned 2026 around applying technology and AI to service delivery while holding down non-labor costs. Widening adjusted margins after a period of integration spending is a key part of the story. Success would let modest revenue growth translate into faster earnings and free-cash-flow growth.
4. Capital returns and cash generation
CBIZ guides to free cash flow in the range of roughly $270 million to $290 million and has boosted share buybacks alongside its raised 2026 adjusted EPS outlook of about $4.00 to $4.10. Debt taken on for Marcum makes deleveraging and steady cash conversion important. Buybacks provide a per-share tailwind if organic growth stays in the low-to-mid single digits.
The bear case: what would have to be true for $42.00
The most pessimistic published target is $42.00, -23.0% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks CBIZ is worth if the risks below bite instead of the drivers above.
CBIZ carries acquisition-related debt from the Marcum deal, so higher-for-longer interest rates and slower deleveraging are a risk to earnings. Organic growth guided at only 2% to 5% leaves little margin for error, and integration, technology, and facility costs have pressured underlying operating margins even as reported profit was helped by one-time acquisition gains that will not recur. The business depends heavily on attracting and retaining accounting, tax, and advisory professionals in a tight labor market, and on middle-market client health that softens in a recession. Regulatory change in tax and benefits, competition from far larger accounting and insurance-brokerage firms, and integration missteps across a much larger combined workforce are additional risks, and the stock has re-rated lower despite raised guidance.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding CBZ already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on CBZ
5 analysts cover CBZ, with an average target of $44.40 (-18.6% against $54.54) and a split of 4 buy, 2 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the CBZ forecast and price target page.
How is CBZ valued? (as of JULY 2026)
Snapshot for CBZ as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$2.8B
- Q1 2026 revenue: ~$848.6M (+1.3% YoY)
- 2026 revenue guidance: ~$2.8B to $2.9B (2-5% growth)
- 2026 adjusted EPS guidance: ~$4.00 to $4.10 (raised)
- 2026 adjusted EBITDA guidance: ~$465M to $475M
- Market cap: ~$2.1B
CBIZ traded around $40 in July 2026, with a trailing P/E near 15 and a forward P/E closer to 9 on guided adjusted earnings, well below its multi-year average multiple. The valuation compression reflects the shift from acquisition-fueled 52% revenue growth in 2025 to guided low-to-mid single-digit organic growth in 2026. Reported quarterly results have at times included large non-operating gains from Marcum acquisition accounting, so adjusted EBITDA and free cash flow are the cleaner gauges of the underlying run-rate.
How do you decide if CBZ is a buy?
Rather than asking whether CBZ is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold CBZ indirectly through an index or sector ETF before adding more.
What would change your mind on CBZ
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Marcum integration and scale synergies stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: cBIZ carries acquisition-related debt from the Marcum deal, so higher-for-longer interest rates and slower deleveraging are a risk to earnings fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the CBZ stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about CBZ against your real portfolio and see your actual exposure before deciding.
Investing in CBIZ with AI
Connect the broker you already use and ask Walnut's AI how CBZ fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is CBZ a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Marcum integration and scale synergies, with revenue (ttm) at ~$2.8B. The bear case rests on cBIZ carries acquisition-related debt from the Marcum deal, so higher-for-longer interest rates and slower deleveraging are a risk to earnings. Analysts covering it are spread from $42.00 to $46.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell CBZ?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. CBIZ carries acquisition-related debt from the Marcum deal, so higher-for-longer interest rates and slower deleveraging are a risk to earnings. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $42.00, -23.0% from the $54.54 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for CBZ?
+
Marcum integration and scale synergies. The 2024 Marcum acquisition roughly doubled CBIZ's size and created the largest middle-market accounting and advisory platform in the US. The most optimistic analyst target on CBZ is $46.00, -15.7% from the $54.54 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for CBZ?
+
CBIZ carries acquisition-related debt from the Marcum deal, so higher-for-longer interest rates and slower deleveraging are a risk to earnings. Organic growth guided at only 2% to 5% leaves little margin for error, and integration, technology, and facility costs have pressured underlying operating margins even as reported profit was helped by one-time acquisition gains that will not recur. The business depends heavily on attracting and retaining accounting, tax, and advisory professionals in a tight labor market, and on middle-market client health that softens in a recession. Regulatory change in tax and benefits, competition from far larger accounting and insurance-brokerage firms, and integration missteps across a much larger combined workforce are additional risks, and the stock has re-rated lower despite raised guidance. The most pessimistic published target is $42.00, -23.0% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does CBIZ do?
+
CBIZ, Inc.
What would have to change for CBZ to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Marcum integration and scale synergies) stalling in the reported numbers rather than in the narrative, the risk above (cBIZ carries acquisition-related debt from the Marcum deal, so higher-for-longer interest rates and slower deleveraging are a risk to earnings) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does CBIZ do?
+
CBIZ, Inc. is a national professional-services firm serving mainly middle-market businesses. It provides accounting and tax, financial advisory and consulting, employee benefits consulting, property and casualty insurance brokerage, and technology and managed IT services, organized into Financial Services, Benefits and Insurance Services, and National Practices segments.
What is the ticker CBZ?
+
CBZ is the NYSE ticker for CBIZ, Inc. The company is a US-listed professional-services advisor, not to be confused with the private accounting partnerships it competes against. It is one of the few publicly traded pure-play middle-market accounting and advisory firms.
Why did CBIZ acquire Marcum?
+
CBIZ closed its acquisition of Marcum LLP in November 2024 in a cash-and-stock deal valued at roughly $2.3 billion, its largest ever. The combination roughly doubled CBIZ's scale, lifted combined annualized revenue toward $2.8 billion, and made it the largest advisor of its kind in the US middle market.
Walnut is informational, not investment advice, and gives no verdict on CBZ. Analyst targets referenced here come from a July 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.